Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Resting left ventricular ejection fraction (LVEF) of 35% or less (determined within 48 months of recruitment by echocardiography, multiple gate acquisition scan (MUGA) or left ventriculogram.)~3. New York Heart Association (NYHA) Class I (with previous symptoms of heart failure), Class II and III~4. Female subjects not menopausal or surgically sterilized will need to have a negative pregnancy test the day before the study day and be on contraception.~Exclusion Criteria:~1. Myocardial infarction (MI) within 3 months of screening.~2. Unstable angina within 14 days of screening, or any evidence of myocardial ischemia.~3. Valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis.~4. Sustained ventricular tachycardia (VT) or ventricular fibrillation (V-fib) within 14 days of screening.~5. Second or third degree atrioventricular (AV) block without a permanent cardiac pacemaker.~6. Cerebrovascular accident (CVA) within 3 months of screening, or other evidence of significantly compromised central nervous system (CNS) perfusion.~7. Serum creatinine of \>3.0 mg/dL.~8. Serum sodium of \<125 milliequivalents per decaLiter (mEq/dL) or \> 160 mEq/dL.~9. Serum potassium of \< 3.5 mEq/dL or \> 5.2 mEq/dL.~10. Serum digoxin level of \> 2.0 ng/ml.~11. Systolic pressure of \<85 mmHg immediately prior to the first injection of study drug/placebo.~12. LVEF \> 35% by within 24 months of screening.~13. Unable to self-administer subcutaneous injection twice a day.~14. Diagnosed with AIDS or known positive HIV titer.~15. Other acute or chronic medical conditions or laboratory abnormality, which may increase the risks, associated with study participation or may interfere with interpretation of the data.~16. Received an investigational drug within 1 month prior to dosing.~17. Unable to undergo cardiac magnetic resonance imaging (MRI). Contraindications to MRI include pacemaker or defibrillator, pregnant women, atrial fibrillation or other arrhythmia, cerebral aneurysm clips, or severe claustrophobia.~18. In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any reasons.~19. Patient in atrial fibrillation or who have a pacemaker or implantable cardioverter defibrillator (ICD)~20. Hemoglobin \< 10g/dl.~21. Patients with an allergy to iodine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B-type Natriuretic Peptide (BNP) (Type: ACTIVE_COMPARATOR): BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo self-administered subcutaneously twice daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete